Lauren S Jones1,2, Marina Serper1. 1. Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine. 2. Philadelphia College of Osteopathic Medicine, Philadelphia, PA.
Abstract
PURPOSE OF REVIEW: We provide an overview of the recent evidence on the prevalence, risk factors, and consequences of medication non-adherence (NA) in liver transplant (LT) recipients. RECENT FINDINGS: NA in LT is associated with socio-demographic and medication-related factors, low social support, and poor health literacy. Patient-reported adherence is one of the most common methods to measure NA using validated assessments; immunosuppression (IS) drug levels and electronic monitoring may also be used. Simplification of IS regimens such as the conversion from twice daily to once daily has been shown to be safe, effective, and improves adherence. Relatively few studies have prospectively investigated NA predictors or interventions to reduce NA in LT. SUMMARY: Medication non-adherence is a multi-faceted issue that is common among LT recipients and associated with adverse outcomes. NA in LT recipients warrants further study as only a few interventions have been published focused on reducing NA in LT.
PURPOSE OF REVIEW: We provide an overview of the recent evidence on the prevalence, risk factors, and consequences of medication non-adherence (NA) in liver transplant (LT) recipients. RECENT FINDINGS: NA in LT is associated with socio-demographic and medication-related factors, low social support, and poor health literacy. Patient-reported adherence is one of the most common methods to measure NA using validated assessments; immunosuppression (IS) drug levels and electronic monitoring may also be used. Simplification of IS regimens such as the conversion from twice daily to once daily has been shown to be safe, effective, and improves adherence. Relatively few studies have prospectively investigated NA predictors or interventions to reduce NA in LT. SUMMARY: Medication non-adherence is a multi-faceted issue that is common among LT recipients and associated with adverse outcomes. NA in LT recipients warrants further study as only a few interventions have been published focused on reducing NA in LT.
Authors: R N Fine; Y Becker; S De Geest; H Eisen; R Ettenger; R Evans; D Lapointe Rudow; D McKay; A Neu; T Nevins; J Reyes; J Wray; F Dobbels Journal: Am J Transplant Date: 2009-01 Impact factor: 8.086
Authors: V Giannelli; M Rossi; M Giusto; C Lucidi; B Lattanzi; A Ruffa; S Ginanni Corradini; G Mennini; F Melandro; Q Lai; P Berloco; M Merli Journal: Eur Rev Med Pharmacol Sci Date: 2013-10 Impact factor: 3.507